189 related articles for article (PubMed ID: 17341535)
1. Gynecomastia associated with fenofibrate.
Gardette V; Vezzosi D; Maiza JC; Montastruc JL; Olivier P
Ann Pharmacother; 2007 Mar; 41(3):508-10. PubMed ID: 17341535
[TBL] [Abstract][Full Text] [Related]
2. Fenofibrate-induced myopathy.
Ghosh B; Sengupta S; Bhattacharjee B; Majumder A; Sarkar SB
Neurol India; 2004 Jun; 52(2):268-9. PubMed ID: 15269493
[TBL] [Abstract][Full Text] [Related]
3. [Fenofibrates and gynaecomastia].
Schmutz JL; Barbaud A; Tréchot P
Ann Dermatol Venereol; 2008 May; 135(5):437. PubMed ID: 18457741
[No Abstract] [Full Text] [Related]
4. [Septic-toxic shock due to rhabdomyolysis in a patient treated with fenofibrate].
Duda-Król W; Jórasz I; Dabrowska M; Polubiec A; Kusz-Rynkun A
Wiad Lek; 2000; 53(7-8):454-7. PubMed ID: 11070769
[TBL] [Abstract][Full Text] [Related]
5. Gynecomastia possibly induced by rosuvastatin.
Oteri A; Catania MA; Travaglini R; Russo A; Giustini SE; Caputi AP; Polimeni G
Pharmacotherapy; 2008 Apr; 28(4):549-51. PubMed ID: 18363539
[TBL] [Abstract][Full Text] [Related]
6. Rare side-effects of fenofibrate.
Rabasa-Lhoret R; Rasamisoa M; Avignon A; Monnier L
Diabetes Metab; 2001 Feb; 27(1):66-8. PubMed ID: 11240449
[TBL] [Abstract][Full Text] [Related]
7. [Chronic lesion of the interlobular bile ducts induced by fenofibrate].
Lepicard A; Mallat A; Zafrani ES; Dhumeaux D
Gastroenterol Clin Biol; 1994; 18(11):1033-5. PubMed ID: 7705563
[TBL] [Abstract][Full Text] [Related]
8. Golf-inhibiting gynecomastia associated with atorvastatin therapy.
Hammons KB; Edwards RF; Rice WY
Pharmacotherapy; 2006 Aug; 26(8):1165-8. PubMed ID: 16863492
[TBL] [Abstract][Full Text] [Related]
9. Rhabdomyolysis caused by Commiphora mukul, a natural lipid-lowering agent.
Bianchi A; Cantù P; Firenzuoli F; Mazzanti G; Menniti-Ippolito F; Raschetti R
Ann Pharmacother; 2004; 38(7-8):1222-5. PubMed ID: 15187214
[TBL] [Abstract][Full Text] [Related]
10. Probable amlodipine-induced angioedema.
Southward J; Irvine E; Rabinovich M
Ann Pharmacother; 2009 Apr; 43(4):772-6. PubMed ID: 19299323
[TBL] [Abstract][Full Text] [Related]
11. Paradoxical decreases in high-density lipoprotein cholesterol with fenofibrate: a quite common phenomenon.
Magee G; Sharpe PC
J Clin Pathol; 2009 Mar; 62(3):250-3. PubMed ID: 19251953
[TBL] [Abstract][Full Text] [Related]
12. A myoclonic reaction with low-dose hydromorphone.
Patel S; Roshan VR; Lee KC; Cheung RJ
Ann Pharmacother; 2006 Nov; 40(11):2068-70. PubMed ID: 17047136
[TBL] [Abstract][Full Text] [Related]
13. Ezetimibe-associated immune thrombocytopenia.
Pattis P; Wiedermann CJ
Ann Pharmacother; 2008 Mar; 42(3):430-3. PubMed ID: 18252832
[TBL] [Abstract][Full Text] [Related]
14. Propofol-induced priapism, a case confirmed with rechallenge.
Vesta KS; Martina SD; Kozlowski EA
Ann Pharmacother; 2006 May; 40(5):980-2. PubMed ID: 16638914
[TBL] [Abstract][Full Text] [Related]
15. [Fenofibrate: animal toxicology in relation to side-effects in man (author's transl)].
Blane GF; Pinaroli F
Nouv Presse Med; 1980 Dec; 9(49):3737-46. PubMed ID: 7208340
[TBL] [Abstract][Full Text] [Related]
16. [Morphometric study of hepatic peroxisomes in hyperlipoproteinemic patients treated with fenofibrate].
Gariot P; Pointel JP; Barrat E; Drouin P; Debry G
Biomed Pharmacother; 1984; 38(2):101-6. PubMed ID: 6743770
[TBL] [Abstract][Full Text] [Related]
17. After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate.
Sacks FM
Am J Cardiol; 2008 Dec; 102(12A):34L-40L. PubMed ID: 19084088
[TBL] [Abstract][Full Text] [Related]
18. Fenofibrate-associated reversible acute allograft dysfunction in 3 renal transplant recipients: biopsy evidence of tubular toxicity.
Angeles C; Lane BP; Miller F; Nord EP
Am J Kidney Dis; 2004 Sep; 44(3):543-50. PubMed ID: 15332227
[TBL] [Abstract][Full Text] [Related]
19. Somnambulism due to probable interaction of valproic acid and zolpidem.
Sattar SP; Ramaswamy S; Bhatia SC; Petty F
Ann Pharmacother; 2003 Oct; 37(10):1429-33. PubMed ID: 14519043
[TBL] [Abstract][Full Text] [Related]
20. Reduced high-density lipoprotein cholesterol in patients receiving rosiglitazone and fenofibrate.
Venero CV; Thompson PD; Fernandez AB
Am J Med; 2008 Oct; 121(10):e3-4. PubMed ID: 18823843
[No Abstract] [Full Text] [Related]
[Next] [New Search]
